Literature DB >> 25488486

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.

Socrates E Papapoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25488486     DOI： 10.1038/nrendo.2014.214

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Authors:  Hua Zhu Ke; William G Richards; Xiaodong Li; Michael S Ominsky
Journal:  Endocr Rev       Date:  2012-06-20       Impact factor: 19.871

2.  Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.

Authors:  Michael S Ominsky; Fay Vlasseros; Jacquelin Jolette; Susan Y Smith; Brian Stouch; George Doellgast; Jianhua Gong; Yongming Gao; Jin Cao; Kevin Graham; Barbara Tipton; Jill Cai; Rohini Deshpande; Lei Zhou; Michael D Hale; Daniel J Lightwood; Alistair J Henry; Andrew G Popplewell; Adrian R Moore; Martyn K Robinson; David L Lacey; W Scott Simonet; Chris Paszty
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

3.  Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.

Authors:  Desmond Padhi; Graham Jang; Brian Stouch; Liang Fang; Edward Posvar
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

4.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

5.  Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.

Authors:  Michael S Ominsky; Qing-Tian Niu; Chaoyang Li; Xiaodong Li; Hua Zhu Ke
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

6.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

7.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Authors:  Joy N Tsai; Alexander V Uihlein; Hang Lee; Ruchit Kumbhani; Erica Siwila-Sackman; Elizabeth A McKay; Sherri-Ann M Burnett-Bowie; Robert M Neer; Benjamin Z Leder
Journal:  Lancet       Date:  2013-05-15       Impact factor: 79.321

8.  Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

Authors:  Benjamin Z Leder; Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Yuli Zhu; Katelyn Foley; Hang Lee; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

9.  A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.

Authors:  Robert R Recker; Charles T Benson; Toshio Matsumoto; Michael A Bolognese; Deborah A Robins; Jahangir Alam; Alan Y Chiang; Leijun Hu; John H Krege; Hideaki Sowa; Bruce H Mitlak; Stephen L Myers
Journal:  J Bone Miner Res       Date:  2015-02       Impact factor: 6.741

Review 10.  Sclerostin: current knowledge and future perspectives.

Authors:  M J C Moester; S E Papapoulos; C W G M Löwik; R L van Bezooijen
Journal:  Calcif Tissue Int       Date:  2010-05-15       Impact factor: 4.333
  10 in total
  11 in total

Review 1.  The past 10 years-new hormones, new functions, new endocrine organs.

Authors:  Roger Bouillon; Daniel J Drucker; Ele Ferrannini; Steven Grinspoon; Clifford J Rosen; Paul Zimmet
Journal:  Nat Rev Endocrinol       Date:  2015-09-01       Impact factor: 43.330

Review 2.  New anabolic therapies for osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Marco Occhiuto; Jessica Pepe
Journal:  Intern Emerg Med       Date:  2017-08-05       Impact factor: 3.397

Review 3.  From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Endocrine       Date:  2016-02-18       Impact factor: 3.633

Review 4.  Sclerostin Inhibition in the Management of Osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Calcif Tissue Int       Date:  2016-03-26       Impact factor: 4.333

Review 5.  Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

6.  Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.

Authors:  D-C Chan; C H-C Chang; L-C Lim; A J M Brnabic; J-Y Tsauo; R Burge; F-Y Hsiao; L Jin; S Gürbüz; R-S Yang
Journal:  Osteoporos Int       Date:  2016-05-12       Impact factor: 4.507

7.  Prevalence of and factors associated with adopting bone health promoting behaviours among people with osteoporosis in Taiwan: a cross-sectional study.

Authors:  Po-Han Chen; Ming-Shyan Lin; Tung-Jung Huang; Mei-Yen Chen
Journal:  BMJ Open       Date:  2017-09-25       Impact factor: 2.692

Review 8.  Profile of romosozumab and its potential in the management of osteoporosis.

Authors:  Sian Yik Lim; Marcy B Bolster
Journal:  Drug Des Devel Ther       Date:  2017-04-13       Impact factor: 4.162

9.  Changes in bone mineral density and bone metabolic indexes in ankylosing spondylitis mouse model complicated with osteoporosis.

Authors:  Zi-Bing Hu; Bo Wei; Shao-Ke Wu; Jie-Cong Sun; Min Xiang; Zhong-Min Zhang
Journal:  Exp Ther Med       Date:  2018-05-24       Impact factor: 2.447

10.  Periodontal Biology: Stem Cells, Bmp2 Gene, Transcriptional Enhancers, and Use of Sclerostin Antibody and Pth for Treatment of Periodontal Disease and Bone Loss.

Authors:  Stephen E Harris; Michael Rediske; Rebecca Neitzke; Audrey Rakian
Journal:  Cell Stem Cells Regen Med       Date:  2017-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.